How effective is T-DM1?

The researchers who led the trial estimated that, at 3 years after beginning adjuvant treatment, 88% of women treated with T-DM1 were alive and free of invasive cancer, compared with 77% of women treated with trastuzumab.

How do you feel after breast cancer diagnosis?

There’s no right or wrong way to feel after a diagnosis of breast cancer. You’ll probably go through many emotions, from fear, shock and anger to disbelief, sadness and numbness. Your emotions may change day to day or even hour to hour.

How long is chemo for early breast cancer?

Typically, if you have early-stage breast cancer, you’ll undergo chemotherapy treatments for three to six months, but your doctor will adjust the timing to your circumstances. If you have advanced breast cancer, treatment may continue beyond six months.

Can you drink alcohol while taking Kadcyla?

You may feel tired or dizzy after your treatment. What NOT to DO while on this medication: DO NOT smoke or drink alcohol while on treatment without talking to your health care team first. Smoking and drinking can make side effects worse and make your treatment not work as well.

Does breast cancer change your personality?

Behavioral symptoms are a common side effect of breast cancer diagnosis and treatment and include disturbances in energy, sleep, mood, and cognition. These symptoms cause serious disruption in patients’ quality of life and may persist for years following treatment.

What kind of breast cancer does T-DM1 treat?

The KATHERINE trial—funded by the manufacturer of T-DM1, Genentech—enrolled nearly 1,500 women with early-stage HER2-positive breast cancer, meaning their cancer was confined to the breast and the axillary lymph nodes. All women in the trial had evidence of residual disease after neoadjuvant therapy, which included chemotherapy and trastuzumab.

How is trastuzumab emtansine used in breast cancer treatment?

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment …

How many women are alive after taking T-DM1?

The researchers who led the trial estimated that, at 3 years after beginning adjuvant treatment, 88% of women treated with T-DM1 were alive and free of invasive cancer, compared with 77% of women treated with trastuzumab.

Are there any side effects to taking T-DM1?

Overall, 18% of women in the T-DM1 group stopped taking the drug because of specific side effects, compared with 2% of women in the trastuzumab group. The increased side effects in women treated with T-DM1, Dr. Geyer noted, was most likely a cumulative effect of the pre- and post-surgical treatments.